Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
52 Results for "
DARS
" in MedChemExpress (MCE) Product Catalog:
Products (52)
52 Results for "DARS" in MCE Product Catalog:
Cat. No.: HY-138298B
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR2) (T-DXd (DAR2); DS-8201 (DAR2); DS-8201a (DAR2)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 2. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-138298C
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR4) (T-DXd (DAR4); DS-8201 (DAR4); DS-8201a (DAR4)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 4. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-138298D
CAS No.: 1826843-81-5
Synonyms: T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)
Target:
Research Areas:
Trastuzumab deruxtecan (DAR6) (T-DXd (DAR6); DS-8201 (DAR6); DS-8201a (DAR6)) is a low-drug-load derivative control preparation of Trastuzumab deruxtecan (HY-138298A) with a drug-to-antibody ratio (DAR) of 6. Trastuzumab deruxtecan (T-DXd; DS-8201a; DS-8201) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
Cat. No.: HY-185774A
Target:
Research Areas:
ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR4) is a control antibody-drug conjugate (ADC) with a drug-to-antibody ratio (DAR) of 4, formed by the conjugation of Human IgG1 (D356E/L358M) kappa, Isotype Control (HY-P990100) and LNK4-S (HY-170400). ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR4) serves as the isotype control for Farletuzumab-LNK4-S (DAR4) (HY-185773A) .
Cat. No.: HY-185774
Target:
Research Areas:
ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR8) is a control ADC with a drug-to-antibody ratio (DAR) of 8, consisting of Human IgG1 (D356E/L358M) kappa, Isotype Control (HY-P990100), which does not specifically bind to FRα, and LNK4-S (HY-170400). ADC Control Human IgG1 (D356E/L358M)-LNK4 (DAR8) serves as the isotype control for Farletuzumab-LNK4-S (DAR8) (HY-185773) .
Cat. No.: HY-185794
Target:
Research Areas:
ADC Control Human IgG1 drozuntecan (DAR 6) is an antibody-drug conjugate control with a drug-to-antibody ratio of 6 .
Cat. No.: HY-101299BR
CAS No.: 137417-08-4
Synonyms: DAR-0100 hydrochloride (Standard)
Target:
Research Areas:
Dihydrexidine (hydrochloride) (Standard) is the analytical standard of Dihydrexidine (hydrochloride) (HY-101299B). This product is intended for research and analytical applications. Dihydrexidine hydrochloride (DAR-0100 hydrochloride) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist, with an IC50 of 10 nM for D1 receptor. Dihydrexidine hydrochloride exhibits potent antiparkinsonian activity . Dihydrexidine hydrochloride can stimulate YAP phosphorylation .
Cat. No.: HY-185830
Research Areas:
ADC Control Human IgG1-vcMMAE (DAR8) is an antibody-drug conjugate (ADCs), serving as an isotype control for ADC human IgG1-vcMMAE, and inhibits tubulin polymerization. The antibody moiety of ADC Control Human IgG1-vcMMAE (DAR8) is Human IgG1 kappa, Isotype Control (HY-P99001), while the cytotoxic payload and linker moiety are VcMMAE (HY-15575). ADC Control Human IgG1-vcMMAE can be used in cancer-related research .
Cat. No.: HY-100554R
CAS No.: 21102-95-4
Research Areas:
BMY 7378 (Standard) is the analytical standard of BMY 7378 (HY-100554). This product is intended for research and analytical applications. BMY 7378 is a selective antagonist of α1D-adrenoceptor (α1D-AR). BMY 7378 binds to membranes expressing the cloned rat α1D-AR with a >100-fold higher affinity (Ki=2 nM) than binding to either the cloned rat α1A-AR (Ki=800 nM) or the hamster α1B-AR (Ki=600 nM). BMY 7378 is a 5-HT1A receptor partial agonist .
Cat. No.: HY-118260
CAS No.: 130905-04-3
Target:
Research Areas:
Phendioxan is a compound with binding activity at the α(1)-adrenaline receptor subtype. The facilitated membrane diffusion of phendioxan is thought to be associated with improved α(1d)-AR affinity. Docking simulations of phendioxan at biological targets supported the stoichiometric analysis and revealed the importance of polar, electrostatic, hydrophobic, and shape effects of its phenoxy terminal orthogonal substituents on ligand binding .
Cat. No.: HY-P12260
CAS No.: 3027489-02-4
Target:
Research Areas:
AJICAP reagent 1b is a thiophenyl ester-based site-specific conjugation reagent for antibody modification applications. AJICAP reagent 1b is used in HER2-positive gastric cancer-related research .
Cat. No.: HY-L165
282 compounds
Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.
MCE designs a unique collection of 282 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
